BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 11789061)

  • 1. Filariasis elimination, Zanzibar.
    Wkly Epidemiol Rec; 2001 Dec; 76(51-52):406-8. PubMed ID: 11789061
    [No Abstract]   [Full Text] [Related]  

  • 2. Towards elimination of lymphatic filariasis: social mobilization issues and challenges in mass drug administration with anti-filarial drugs in Tamil Nadu, South India.
    Nandha B; Krishnamoorthy K; Jambulingam P
    Health Educ Res; 2013 Aug; 28(4):591-8. PubMed ID: 23503571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Report on the mid-term assessment of microfilaraemia reduction in sentinel sites of 13 countries of the Global Programme to Eliminate Lymphatic Filariasis.
    Wkly Epidemiol Rec; 2004 Oct; 79(40):358-65. PubMed ID: 15631012
    [No Abstract]   [Full Text] [Related]  

  • 4. GlaxoSmithKline and Merck: private-sector collaboration for the elimination of lymphatic filariasis.
    Gustavsen KM; Bradley MH; Wright AL
    Ann Trop Med Parasitol; 2009 Oct; 103 Suppl 1():S11-5. PubMed ID: 19843393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Global Programme to Eliminate Lymphatic Filariasis: health impact during its first 8 years (2000-2007).
    Hooper PJ; Bradley MH; Biswas G; Ottesen EA
    Ann Trop Med Parasitol; 2009 Oct; 103 Suppl 1():S17-21. PubMed ID: 19843394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of ivermectin and albendazole combination in suppressing transmission of lymphatic filariasis following mass administration in Tanzania: a prospective cohort study.
    Fimbo AM; Mnkugwe RH; Mlugu EM; Kunambi PP; Malishee A; Minzi OMS; Kamuhabwa AAR; Aklillu E
    Infect Dis Poverty; 2024 Jun; 13(1):44. PubMed ID: 38867265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphatic filariasis elimination programme in India: progress and challenges.
    Ramaiah KD
    Trends Parasitol; 2009 Jan; 25(1):7-8. PubMed ID: 19008150
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of albendazole in programmes to eliminate lymphatic filariasis.
    Ottesen EA; Ismail MM; Horton J
    Parasitol Today; 1999 Sep; 15(9):382-6. PubMed ID: 10461168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.
    Fischer PU; King CL; Jacobson JA; Weil GJ
    PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005163. PubMed ID: 28056015
    [No Abstract]   [Full Text] [Related]  

  • 10. Endpoints for lymphatic filariasis programs.
    Grady CA; de Rochars MB; Direny AN; Orelus JN; Wendt J; Radday J; Mathieu E; Roberts JM; Streit TG; Addiss DG; Lammie PJ
    Emerg Infect Dis; 2007 Apr; 13(4):608-10. PubMed ID: 17553278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of Lymphatic Filariasis and Treatment Effectiveness of Albendazole/ Ivermectin in Individuals with HIV Co-infection in Southwest-Tanzania.
    Kroidl I; Saathof E; Maganga L; Clowes P; Maboko L; Hoerauf A; Makunde WH; Haule A; Mviombo P; Pitter B; Mgeni N; Mabuye J; Kowuor D; Mwingira U; Malecela MN; Löscher T; Hoelscher M
    PLoS Negl Trop Dis; 2016 Apr; 10(4):e0004618. PubMed ID: 27070786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development of albendazole for lymphatic filariasis.
    Horton J
    Ann Trop Med Parasitol; 2009 Oct; 103 Suppl 1():S33-40. PubMed ID: 19843396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for the use of albendazole for the elimination of lymphatic filariasis.
    Sunish IP; Rajendran R; Mani TR; Dash AP; Tyagi BK
    Lancet Infect Dis; 2006 Mar; 6(3):125-6. PubMed ID: 16500593
    [No Abstract]   [Full Text] [Related]  

  • 14. Lymphatic filariasis control in Tanzania: effect of six rounds of mass drug administration with ivermectin and albendazole on infection and transmission.
    Simonsen PE; Derua YA; Kisinza WN; Magesa SM; Malecela MN; Pedersen EM
    BMC Infect Dis; 2013 Jul; 13():335. PubMed ID: 23870103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress towards eliminating lymphatic filariasis in Zanzibar: a model programme.
    Mohammed KA; Molyneux DH; Albonico M; Rio F
    Trends Parasitol; 2006 Jul; 22(7):340-4. PubMed ID: 16713740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospects for elimination of bancroftian filariasis by mass drug treatment in Pondicherry, India: a simulation study.
    Stolk WA; Swaminathan S; van Oortmarssen GJ; Das PK; Habbema JD
    J Infect Dis; 2003 Nov; 188(9):1371-81. PubMed ID: 14593597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fifteen years of programme implementation for the elimination of Lymphatic Filariasis in Ghana: Impact of MDA on immunoparasitological indicators.
    Biritwum NK; de Souza DK; Marfo B; Odoom S; Alomatu B; Asiedu O; Yeboah A; Hervie TE; Mensah EO; Yikpotey P; Koroma JB; Molyneux D; Bockarie MJ; Gyapong JO
    PLoS Negl Trop Dis; 2017 Mar; 11(3):e0005280. PubMed ID: 28333930
    [No Abstract]   [Full Text] [Related]  

  • 18. Early-stage elephantiasis in bancroftian filariasis.
    Grobusch MP; Göbels K; Teichmann D; Bergmann F; Suttorp N
    Eur J Clin Microbiol Infect Dis; 2001 Nov; 20(11):835-6. PubMed ID: 11783706
    [No Abstract]   [Full Text] [Related]  

  • 19. Global programme to eliminate lymphatic filariasis.
    World Health Organization
    Wkly Epidemiol Rec; 2005 Jun; 80(23):202-12. PubMed ID: 16033148
    [No Abstract]   [Full Text] [Related]  

  • 20. Elimination of lymphatic filariasis as a public health problem.
    Cox FE
    Parasitol Today; 2000 Apr; 16(4):135. PubMed ID: 10725894
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.